Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Chemoradiation in Locally Advanced Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Biological: recombinant interferon alfa
Drug: cisplatin
Drug: fluorouracil
Radiation: radiation therapy
Procedure: Resection of tumor

First Posted Date: 2005-12-07

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 23

Registration Number: NCT00262951

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2005-11-24

Last Posted Date: 2015-09-30

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 80

Registration Number: NCT00258323

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Cetuximab

First Posted Date: 2005-11-11

Last Posted Date: 2019-02-15

Lead Sponsor: US Oncology Research

Target Recruit Count: 247

Registration Number: NCT00252564

Locations: 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸
Hematology Oncology Associates of Ohio & Michigan, Lambertville, Michigan, United States

and more 75 locations

Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: 5-Fluorouracil
Procedure: Radiation Therapy

First Posted Date: 2005-11-10

Last Posted Date: 2016-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00251355

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

Phase 1

Completed

Conditions: Neoplasms, Advanced

Interventions: Drug: Valproic acid
Drug: Epirubicin
Drug: 5-fluorouracil
Drug: Cyclophosphamide.

First Posted Date: 2005-10-30

Last Posted Date: 2017-02-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 82

Registration Number: NCT00246103

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer

Phase 3

Withdrawn

Conditions: Localized Resectable Adult Primary Liver Cancer
Stage III Childhood Liver Cancer

First Posted Date: 2005-10-13

Last Posted Date: 2013-05-30

Lead Sponsor: Kyoto University

Registration Number: NCT00238160

Locations: 🇯🇵
Kyoto-Katsura Hospital, Kyoto, Japan
🇯🇵
Kyoto Prefectural University of Medicine, Kyoto, Japan
🇯🇵
Kyoto City Hospital, Kyoto, Japan

and more 1 locations

Clinical Trial in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: CoFactor
Drug: 5-FU
Drug: Leucovorin

First Posted Date: 2005-10-12

Last Posted Date: 2008-08-25

Lead Sponsor: Mast Therapeutics, Inc.

Target Recruit Count: 300

Registration Number: NCT00235898

Locations: 🇮🇳
Department of Oncology, Christian Medical College, Vellore, Tamil Nadu, India
🇮🇳
Global Hospital, Hyderabad, Andhra Pradesh, India
🇷🇸
Clinic for Internal Medicine, Institute for Oncology Sremska, Sremska Kamenica, Serbia

and more 27 locations

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Phase 2

Completed

Conditions: Esophageal Cancer

First Posted Date: 2005-09-30

Last Posted Date: 2010-01-15

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT00230451

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2

Terminated

Conditions: Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Lung Cancer
Neoplastic Syndrome
Neuroendocrine Tumor

Interventions: Biological: bevacizumab
Drug: 5-fluorouracil
Drug: leucovorin
Drug: oxaliplatin

First Posted Date: 2005-09-28

Last Posted Date: 2023-05-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 36

Registration Number: NCT00227617

Locations: 🇺🇸
Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States
🇺🇸
Univeristy of California, San Francisco, San Francisco, California, United States

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Phase 3

Active, not recruiting

Conditions: Colon Mucinous Adenocarcinoma
Colon Signet Ring Cell Adenocarcinoma
Lynch Syndrome
Stage IIA Colon Cancer AJCC v7
Stage IIB Colon Cancer AJCC v7
Stage IIC Colon Cancer AJCC v7

Interventions: Drug: Fluorouracil
Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin

First Posted Date: 2005-09-22

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3610

Registration Number: NCT00217737

Locations: 🇺🇸
Dana Farber Community Cancer Care-Stoneham, Stoneham, Massachusetts, United States
🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Genesis Cancer Care Institute, Davenport, Iowa, United States

and more 921 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy